U.S., Oct. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07859735) titled 'A Study to Investigate the Effects of Impaired Hepatic Function on Velzatinib' on Oct. 01.
Brief Summary: This study evaluates the pharmacokinetics (PK), safety, and tolerability of velzatinib in participants with mild, moderate, and severe hepatic impairment (HI) and participants with normal hepatic function.
Study Start Date: Nov. 10
Study Type: INTERVENTIONAL
Condition:
Healthy Participants
Gastrointestinal Neoplasms
Intervention:
DRUG: Velzatinib
Velzatinib will be administered
Recruitment Status: NOT_YET_RECRUITING
Sponsor: GlaxoSmithKline
Disclaimer: Curated by HT Syndication....